/PRNewswire/ Due to the excellent development of its core business, additional demand generated by the coronavirus pandemic, and several acquisitions, the.
/PRNewswire/ Due to the excellent development of its core business, additional demand generated by the coronavirus pandemic, and several acquisitions, the.
Due to the excellent development of its core business, additional demand generated by the coronavirus pandemic, and several acquisitions, the life science group Sartorius closed fiscal 2021 with e .
/PRNewswire/ The life science group Sartorius has continued to grow dynamically and profitably. For the nine-month reporting period of 2021, the company.
Share this article
Share this article
GÖTTINGEN, Germany, July 21, 2021 /PRNewswire/ The life science Group Sartorius has continued on its fast growth trajectory, closing the first half of 2021 with significant double-digit increases in both sales revenue and order intake
1. In the first six months of the year, we have seen unabated high demand for innovative technologies used in the development and production of biopharmaceuticals. Orders from customers who manufacture coronavirus vaccines and coronavirus test kits have played an additional important, though not dominant, role in this respect. The acquisitions closed in 2020 also are performing well and have added positive momentum. Our most recent acquisition of a majority stake in CellGenix, a leading global supplier of GMP–grade cell culture components, enables us to provide our customers with even more comprehensive support in moving their drug candidates quickly and efficiently through the various steps of drug devel